SDX 7320

Drug Profile

SDX 7320

Alternative Names: MetAP2 inhibitor - SynDevRx; Methionine aminopeptidase type II - SynDevRx; SDX-7320

Latest Information Update: 27 Apr 2016

Price : $50

At a glance

  • Originator SynDevRx, Inc
  • Class
  • Mechanism of Action DNA synthesis inhibitors; Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Feb 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Refractory metastatic disease) in USA (SC) (NCT02743637)
  • 25 May 2011 SynDevRX files for patent protection for SDX 7320 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top